Evidence map›Paper›PMID 33443663›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2021

Evaluation of clinical findings and neurofibromatosis type 1 bright objects on brain magnetic resonance images of 60 Turkish patients with NF1 gene variants.

Filiz Hazan, Semra Gürsoy, Aycan Unalp, Unsal Yılmaz, Bengü Demirağ, Sultan Aydin Köker, Berk Ozyılmaz, Kadri Murat Erdogan, Önder Kalenderer, Serkan Erkuş and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Filiz HazanDepartment of Medical Genetics, Dr. Behcet Uz Children's Hospital, Izmir, Turkey.
Semra GürsoyDepartment of Pediatric Genetics, Dr. Behcet Uz Children's Hospital, Izmir, Turkey.
Aycan UnalpDepartment of Pediatric Neurology, Dr. Behcet Uz Children's Hospital, Izmir, Turkey.
Unsal YılmazDepartment of Pediatric Neurology, Dr. Behcet Uz Children's Hospital, Izmir, Turkey.
Bengü DemirağDepartment of Pediatric Hematology and Oncology, Dr. Behcet Uz Children's Hospital, Izmir, Turkey.
Sultan Aydin KökerDepartment of Pediatric Hematology and Oncology, Dr. Behcet Uz Children's Hospital, Izmir, Turkey. drsultanaydin@hotmail.com.ORCID http://orcid.org/0000-0002-8801-7776
Berk OzyılmazDepartment of Medical Genetics, Tepecik Training and Research Hospital, Izmir, Turkey.
Kadri Murat ErdoganDepartment of Medical Genetics, Tepecik Training and Research Hospital, Izmir, Turkey.
Önder KalendererDepartment of Orthopaedics and Traumatology, Tepecik Training and Research Hospital, Izmir, Turkey.
Serkan ErkuşDepartment of Orthopaedics and Traumatology, Tepecik Training and Research Hospital, Izmir, Turkey.
Müge GürçınarDepartment of Radiology, Alsancak Imaging Center, Izmir, Turkey.
Ajlan TükünDivision of Medical Genetics, Duzen Laboratories Group, Ankara, Turkey.
Dr. Behçet Uz Çocuk Hastalıkları Hastanesi · TRIntergen (Turkey) · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurofibromatosis type 1 (NF1) is caused by mutations in the NF1 gene. This retrospective study aims to evaluate the clinical manifestations and brain magnetic resonance images (MRI) analysis in 60 genetically confirmed NF1 patients. The results of next-generation sequencing (NGS), Sanger sequencing, and MLPA of NF1 gene were evaluated. A total of 54 different variants were identified. Fourteen out of them were novel variants (25.9%). Patients who complied with NIH criteria had most frequently frameshift variants (11/32 patients), and those with only CALMs had missense variants (9/28 patients). Neurofibromatosis type 1 bright objects (NBOs) on T2-weighted MRI were detected in 42 patients (42/56; 75%). These brain lesions were detected mostly in basal ganglia and in cerebellar vermis. NBOs were detected more in the patients who complied with NIH criteria (80.6%) compared to those who were only CALMs (68%). While frameshift variants (33.3%) were the most common type variants in the patients who had NBOs, the most common variants were splicing (35.7%) and missense (35.7%) variants in the patients whose MRIs were normal. Frameshift variants (11/28 patients; 39.3%) were the most common in the patients with more than one brain locus involvement. Therefore, we consider that frameshift variants may be associated with increased incidence of NBOs and involvement of more than one brain locus. In addition, NBOs may occur less frequently in the patients with splicing variants. To our knowledge, this is the first study evaluated the relationship between NF1 gene variants and NBOs. Future studies may help us understand the etiology of NBOs.

Indexed as

Neurofibromatosis 1BrainGenes, Neurofibromatosis 1HumansMagnetic Resonance ImagingNeurofibromin 1Retrospective StudiesNeurofibromin 1NF1 protein, humanBrain magnetic resonance imagesCafé-au-lait maculesNBOsNF1 geneVariants

Identifiers

PMID33443663
OpenAlexW3119196088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.